Paclitaxel-Coated Versus Sirolimus-Coated Eluting Balloons for Percutaneous Coronary Interventions: Pharmacodynamic Properties, Clinical Evidence, and Future Perspectives
Future Pharmacology · 02.11.2024 · 4 (4) · 775-787
DOI: 10.3390/futurepharmacol4040041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Pharmacology, online erschienen am 02.11.2024. Verfasst von Filippo Luca Gurgoglione und 11 weiteren Autor:innen. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Drug-coated balloons (DCBs) have emerged as an increasingly valuable option for the treatment of coronary artery disease (CAD). Percutaneous coronary intervention (PCI) with DCBs enables the localized delivery of antiproliferative drugs directly to the target coronary lesion, avoiding the need for permanent scaffold implantation. Historically, paclitaxel-coated balloons (PCBs) have been the most used device in this context. Paclitaxel interferes with intracellular microtubule function, leading to cell cycle arrest. However, its cytotoxicity at a higher dosage and narrow therapeutic range has raised some safety concerns. To address these issues, sirolimus-coated balloons (SCBs) have been introduced as an alternative. Sirolimus acts as a cytostatic agent with potent anti-inflammatory and antiproliferative properties and is characterized by a wider therapeutic range, potentially offering a safer profile. Several experimental and clinical studies comparing the safety and efficacy of PCBs versus SCBs have yielded mixed results. Recently, a novel DCB (SirPlux Duo), which simultaneously releases both paclitaxel and sirolimus, has been tested in a porcine coronary model with promising results. In this review, we will elucidate the mechanisms of action of paclitaxel and sirolimus, examine contemporary preclinical and clinical evidence comparing PCB and SCB angioplasty, and discuss novel devices that may enhance the safety and efficacy of PCI with DCBs.
Zitieren
APA
Gurgoglione, F. L., Gregorio, M. D., Benatti, G., Donelli, D., Vignali, L., Solinas, E., Tadonio, I., Denegri, A., Covani, M., Dallaglio, G., Cortese, B., & Niccoli, G. (2024). Paclitaxel-Coated Versus Sirolimus-Coated Eluting Balloons for Percutaneous Coronary Interventions: Pharmacodynamic Properties, Clinical Evidence, and Future Perspectives. Future Pharmacology, 4(4), 775-787. https://doi.org/10.3390/futurepharmacol4040041
Vancouver
Gurgoglione FL, Gregorio MD, Benatti G, Donelli D, Vignali L, Solinas E, et al. Paclitaxel-Coated Versus Sirolimus-Coated Eluting Balloons for Percutaneous Coronary Interventions: Pharmacodynamic Properties, Clinical Evidence, and Future Perspectives. Future Pharmacology. 2024;4(4):775-787. doi:10.3390/futurepharmacol4040041
BibTeX
@article{Gurgoglione2024,
author = {Gurgoglione, Filippo Luca and Gregorio, Mattia De and Benatti, Giorgio and Donelli, Davide and Vignali, Luigi and Solinas, Emilia and Tadonio, Iacopo and Denegri, Andrea and Covani, Marco and Dallaglio, Gabriella and Cortese, Bernardo and Niccoli, Giampaolo},
title = {Paclitaxel-Coated Versus Sirolimus-Coated Eluting Balloons for Percutaneous Coronary Interventions: Pharmacodynamic Properties, Clinical Evidence, and Future Perspectives},
journal = {Future Pharmacology},
year = {2024},
volume = {4},
number = {4},
pages = {775--787},
doi = {10.3390/futurepharmacol4040041}
}
EUVIMED